iCAD to highlight AI for tomosynthesis at ECR

iCAD plans to highlight its artificial intelligence (AI) software for digital breast tomosynthesis (DBT), ProFound AI, at the upcoming ECR 2019 in Vienna.

The software was cleared on 7 December 2018 by the U.S. Food and Drug Administration (FDA). It detects malignant soft-tissue densities and calcifications while offering radiologists scoring information that indicates the likelihood that a detection or case is malignant, the company said.

At the meeting, iCAD will also preview ProFound AI for 2D mammography, currently pending the CE Mark.

Page 1 of 130
Next Page